###### Strengths and limitations of this study

-   Our data set comprised of a large population representative of acute venous thromboembolism (VTE) discharged directly from emergency departments (EDs) and reflects practices over the span of a full year from Edmonton, Alberta, Regina, Saskatchewan and rural Alberta identified by reviewing each medical record.

-   Individual chart audits enabled strict inclusion of acute VTE to accurately identify real-world practices.

-   Inclusion of two urban centres (one with referral-based VTE outpatient clinics and one without) and rural Alberta (emergency department staffed by primary care physicians) offers insight into varying practices for the management of acute VTE.

-   Assessing practice patterns via retrospective medical record review limited us to documentation within ED charting, thereby preventing us from identifying all a priori data elements for each patient (eg, weight) and not enabling us to assess outcomes once they left the ED.

Introduction {#s1}
============

Acute venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is common, impacting up to 5% of the population.[@R1] After nearly 60 years with a parenteral anticoagulant±warfarin as the only option for the treatment of acute VTE, there are now four direct oral anticoagulants (DOACs)[@R2] that have demonstrated non-inferiority for the prevention of recurrent VTE or VTE-related death and have major bleeding rates that are similar or less to that experienced with traditional care.[@R6] In Canada, approval of the DOACs began in February 2012 with rivaroxaban for DVT and the PE indication followed in April of 2013; dabigatran came to market in June of 2014, apixaban in November of 2014 and, lastly, edoxaban in November of 2016. While the drug--dose sequence may complicate care delivery, the DOACs offer many practical advantages over traditional therapy (parenteral anticoagulation±warfarin). The DOACs do not require ongoing routine coagulation/laboratory testing, and apixaban and rivaroxaban have the added benefit of not requiring initial therapy with a parenteral anticoagulant. Most recent North American guidelines (2016) recommend the DOACs be used in preference to warfarin for the acute treatment of VTE in patients without cancer patients.[@R3]

Little, if any, data is available to assess physician practices pertaining to the use of DOACs for the acute management of VTE for patients discharged directly from the Emergency Department (ED). Moreover, it is not known if practices are similar between urban cities and rural sites. Given the ability of these agents to streamline care delivery, we hypothesised an early uptake of DOACs that was expected to be similar between urban cities yet greater in rural sites given the convenience of no routine laboratory monitoring and the ability to reach a smaller group of physicians for information dissemination.

Methods {#s2}
=======

Data sources {#s2a}
------------

Retrospective medical record reviews for each institution were performed to capture all data from the hospital-based chart. Data elements included patient demographics, type and severity of DVT or PE, anticoagulant prescribed at discharge and plan for follow-up in the community. Given this study spanned two urban cites and rural sites, three data extractors were required and all data were entered into a Research Electronic Data Capture (REDCap) database.[@R13] The REDCap database was programmed for mandatory field entries, restrictions/limits for data fields and reports were run to allow quality assurance checks on all entered data. Missing data elements (weight, creatinine clearance (Cr Cl)) were tracked, and are identified herein.

Study setting {#s2b}
-------------

This retrospective chart review encompassed hospitals representative of a collaboration of colleagues with similar interests and practices. These included the four largest hospitals in the Edmonton, Alberta area (University of Alberta Hospital, Royal Alexandra Hospital, Misericordia Hospital, Grey Nuns Hospital; population of 1 328 290 plus catchment of \~500 000),[@R14] the two academic hospitals in Regina, Saskatchewan (Regina General Hospital and Pasqua Hospital; population 230 020 plus catchment area of 500 000)[@R15] and three rural hospitals in Alberta (Wetaskiwin Hospital, population 12 621; Westlock Healthcare Centre, population 4823 and Athabasca Healthcare Centre, population \~3000) in which the provision of emergency services is provided by primary care physicians with a private family medicine practices in the community.[@R16] Data were combined and presented separately for each setting, namely Edmonton, Regina and rural Alberta, to enable comparisons between the two urban settings in different provinces with different health authorities (namely Edmonton and Regina) and the rural setting. For Edmonton, data were further broken down into academic sites (University of Alberta Hospital, Royal Alexandra Hospital) and community-based hospitals (Misericordia Hospital, Grey Nuns Hospital) given that two academic centres both have hospital-based ambulatory VTE clinics that accept referrals directly from the ED for patients newly diagnosed with VTE and it was hypothesised that anticoagulant therapies selected at discharge and planned follow-up patterns in the community may be different than that of the community hospitals. No other hospitals (cities) included in this study contained an ambulatory VTE clinic for referral of patients with newly diagnosed VTE.

Patient population {#s2c}
------------------

All patients discharged directly from the ED with an acute VTE (identified by ICD-10 codes I82 (DVT) or I26 (PE) with all subindices) from 1 April 2014 through 31 March 2015 were screened. Patients were excluded if they had atypical clot locations (eg, axillary/subclavian veins), another indication for therapeutic anticoagulation, an anticipated lifespan \<3 months (documentation of palliation or prognosis), were not discharged alive, \<18 years of age, were pregnant/breastfeeding or were admitted to the hospital.

Outcomes {#s2d}
--------

Primarily, we assessed the proportion of patients discharged directly from the ED that were prescribed either traditional therapy (parenteral anticoagulant±warfarin) or a DOAC, with comparisons between Edmonton, Regina and rural Alberta. Within Edmonton, these data were further compared for academic and community-based hospitals. Secondarily, selection of anticoagulant therapies was compared in relation to DVT versus PE, based on Cr Cl (\<30, 30--50 and \>50 mL/min) as well as the burden of the clot. For DVT, clot burden was broken down based on being proximal (at or above the popliteal vein) or distal in the leg. For PE, presentation was assessed using two methods based on documentation at the point of PE diagnosis. First, we used the validated simplified Pulmonary Embolism Severity Indices (sPESI) of 0 or ≥1.[@R19] Second, we categorised them as massive (sustained hypotension (systolic \<90 mm Hg for at least 15 min), pulselessness, persistent profound bradycardia (\<40 beats per minute with signs/symptoms of shock)), submassive (no hypotension yet the presence of right ventricular dysfunction evidenced by right ventricular dilation or myocardial ischaemia evidenced by elevation of biomarkers such as Brain Natureitc Peptide (BNP) or troponins) or low risk (normotensive, with no criteria previously stated).[@R21] Lastly, we assessed the dosing for DOACs as per Health Canada-approved product monographs (when applicable) and with whom follow-up was to occur in the community.

While these data detail the management of acute VTE for those directly discharged from the ED, we also audited records for those hospitalised with acute VTE within these institutions. Our a priori evaluation plan also encompassed an aggregate comparison of urban centres (Regina and Edmonton area only) among those discharged directly from the ED versus those hospitalised,[@R22] as well as an evaluation of those hospitalised.[@R23]

Patient and public involvement statement {#s2e}
----------------------------------------

Patients and or the public were not involved in this study.

Analysis {#s2f}
--------

Data analysis was performed at the Epidemiology Coordinating and Research Centre. All data within REDCap are at the University of Alberta, and are available to the principal investigator (TJB). No data sharing agreement is in place. Patients' characteristics were compared between sites using mean (SD) or median (IQR) as appropriate for the continuous data and proportions (%) for categorical data. The χ^2^ test was used to compare discharge therapies between sites and different groups. Statistical analysis was performed using SAS V.9.4.

Results {#s3}
=======

After screening 1723 patients, 417 (24.2%) were included ([figure 1](#F1){ref-type="fig"}). Most patients (85.8%) were excluded as VTE was not diagnosed. Those in rural Alberta were older (68 years) and spent less time in the ED (\~2 hours) compared with Edmonton (56 years; \~6 hours) and Regina (60 years; 6 hours) ([table 1](#T1){ref-type="table"}). Overall, the mean patient weight was 84 kg, and the majority (86.6%) had normal renal function. A greater proportion of patients discharged directly from the ED had PE in Edmonton (43.4%), compared with Regina (7%) or rural Alberta (20%). The majority with PE (66.4%) had a sPESI score of 0. Distal DVTs were much less common in the Edmonton sites (9.3%) compared with Regina (40.3%), potentially attributable to whole leg ultrasounds being performed in Regina, whereas proximal leg ultrasounds are standard of care in Alberta.

![Patient flow. VTE, venous thromboembolism.](bmjopen-2018-022064f01){#F1}

###### 

Baseline characteristics

                                  All               Edmonton            Rural Alberta       Regina
  ------------------------------ ----------------- ------------------- ------------------- --------------------
  Screened (N)                   1723              1371                185                 167
  Included (N, %)                417 (24.2%)       304 (22.2%)         30 (16.2%)          83 (49.7%)
  Male (N, %)                    220 (52.8%)       156 (51.3%)         14 (46.7%)          50 (60.2%)
  Mean±SD age                    58.0±18.1         56.3±18.5           67.6±14.7           60.4±16.4
  Hours in ED---median (range)   6 (4.0, 8.5)      6.3 (4.4, 9.0)      2.2 (1.2, 3.5)      6.0 (4.5, 8.3)
  Weight done (N, %)\*           300 (71.9%)       204 (67.1%)         19 (63.3%)          77 (92.8%)
  Weight (median)                84 (68.1, 99.3)   81.6 (67.5, 98.5)   73.0 (68.0, 93.0)   87.0 (77.0, 103.0)
  Cr Cl (N,%)\*                  328 (78.7%)       235 (77.3%)         22 (73.3%)          71 (85.5%)
   \<30 mL/min                   10 (3.0%)         7 (3.0%)            2 (9.1%)            1 (1.4%)
   30--49 mL/min                 34 (10.4%)        21 (8.9%)           5 (22.7%)           8 (11.3%)
   \>50 mL/min                   284 (86.6%)       207 (88.1%)         15 (68.2%)          62 (87.3%)
  VTE                                                                                      
   DVT                           273 (65.5%)       172 (56.6%)         24 (80.0%)          77 (92.8%)
    Distal                       52 (19.0%)        16 (9.3%)           7 (33.3%)           29 (40.3%)
    Proximal†                    204 (74.7%)       147 (85.5%)         14 (66.7%)          43 (59.7%)
    Not documented               17 (6.2%)         9 (5.2%)            3 (12.5%)           5 (6.5%)
   PE and PE+DVT‡                144 (34.5%)       132 (43.4%)         6 (20.0%)           6 (7.2%)
  PE---simplified PESI Score                                                               
   0 point                       96 (66.6%)        92 (69.7%)          1 (16.7%)           3 (50.0%)
   ≥1 points                     48 (33.6%)        40 (30.3%)          5 (83.3%)           3 (50.0%)
  History of                                                                               
   Prior VTE                     92 (22.1%)        68 (22.4%)          6 (20.0%)           18 (21.7%)
   Cancer                        64 (15.3%)        44 (14.5%)          7 (23.3%)           13 (15.7%)
   Pulmonary disease             41 (9.8%)         34 (11.2%)          2 (6.7%)            5 (6.0%)
   Recent surgery                30 (7.2%)         23 (7.6%)           1 (3.3%)            6 (7.2%)

\*Not all patients had weight and serum creatinine documented in the chart.

†Combined popliteal, femoral, common femoral and iliac.

‡PE and PE+DVT are reported together.

Cr Cl, creatinine clearance; DVT, deep vein thrombosis; ED, emergency department; PE, pulmonary embolism; PESI, Pulmonary Embolism Severity Index; VTE, venous thromboembolism.

Among all sites, traditional therapy (parenteral anticoagulant±warfarin) was most commonly used (70.7%), with DOACs being prescribed to 27.8% ([table 2](#T2){ref-type="table"}). Among the urban centres, Regina transitioned most patients to warfarin (75.9%), while Edmonton sites more commonly discharged patients on parenteral anticoagulant therapy alone (51.6%). Within Edmonton, the academic sites prescribed more parenteral therapy alone (60.6%) than community-based sites (41.0%) and less DOACs (20.6% vs 40.3%, respectively). Academic sites more commonly referred to VTE clinics (80.6% and 33.8%), respectively ([table 3](#T3){ref-type="table"}). Primary care physicians in rural Alberta EDs had the highest rate of DOAC use (53.3%), while Regina had the lowest (12.1%). Of the DOACs, rivaroxaban was most frequently used (95.7%) with the remainder being apixaban (4.1%).

###### 

Discharge therapy and follow-up

  VTE specified                        Total         Edmonton      Rural Alberta   Regina       P values
  ------------------------------------ ------------- ------------- --------------- ------------ ----------
  VTE (all combined)                                                                            p\<0.001
   Parenteral anticoagulant alone      172 (41.2%)   157 (51.6%)   6 (20.0%)       9 (10.8%)    
   Parenteral anticoagulant+warfarin   123 (29.5%)   52 (17.1)     8 (26.7%)       63 (75.9%)   
   DOAC                                116 (27.8%)   90 (29.6%)    16 (53.3%)      10 (12.1%)   
    Rivaroxaban                        111 (95.7%)   87 (96.7%)    15 (93.8%)      9 (90.0%)    
    Apixaban                           5 (4.3%)      3 (3.3%)      1 (6.3%)        1 (10.0%)    
   Not documented                      6 (1.4%)      5 (1.6%)      0               1 (1.2%)     
  PE and PE+DVT                                                                                 p=0.55
   Parenteral anticoagulant alone      71 (49.3%)    64 (48.5%)    3 (50.0%)       4 (66.7%)    
   Parenteral anticoagulant+warfarin   20 (13.9%)    18 (13.6%)    2 (33.3%)       0            
   DOAC                                49 (34.0%)    46 (34.8%)    1 (16.7%)       2 (33.3%)    
    Rivaroxaban                        47 (95.9%)    44 (95.7%)    1 (100.0%)      2 (100.0%)   
    Apixaban                           2 (4.1%)      2 (4.3%)      0               0            
   Not documented                      4 (2.8%)      4 (3.0%)      0               0            
  DVT alone                                                                                     p\<0.001
   Parenteral anticoagulant alone      101 (36.9%)   93 (54.1%)    3 (12.5%)       5 (6.5%)     
   Parenteral anticoagulant+warfarin   103 (37.7%)   34 (19.8%)    6 (25.0%)       63 (81.8%)   
   DOAC                                67 (24.5%)    44 (25.6%)    15 (62.5%)      8 (10.4%)    
    Rivaroxaban                        64 (95.5%)    43 (97.7%)    14 (93.3%)      7 (87.7%)    
    Apixaban                           3 (5.4%)      1 (2.3%)      1 (6.7%)        1 (12.5%)    
   Not documented                      2 (0.7%)      1 (0.1%)      0               1 (1.3%)     
  Follow-up\*                                                                                   
   Family doctor                       124 (26.8%)   61 (20.1%)    16 (53.3%)      47 (56.6%)   
   Return to ED                        16 (3.4%)     5 (1.6%)      7 (23.3%)       4 (4.8%)     
   Specialist                          25 (5.4%)     13 (4.3%)     1 (3.3%)        11 (13.3%)   
   VTE clinic                          186 (40.2%)   180 (59.2%)   0               0            
   Anticoagulation clinic              19 (4.1%)     3 (1.0%)      1 (3.3%)        15 (18.1%)   
   Other                               55 (11.9%)    44 (14.5%)    1 (3.3%)        10 (12.0%)   
   Not documented                      37 (8.0%)     23 (7.6%)     5 (16.7%)       9 (10.8%)    

\*Not mutually exclusive.

DOAC, direct oral anticoagulant; DVT, deep vein thrombosis; ED, emergency department; PE, pulmonary embolism; VTE, venous thromboembolism.

###### 

Edmonton comparison of academic with community-based hospitals

  VTE specified                        Edmonton academic sites   Edmonton community-based sites   P values
  ------------------------------------ ------------------------- -------------------------------- ----------
  VTE (all combined)                                                                              p=0.0004
   Parenteral anticoagulant alone      100 (60.6%)               57 (41.0%)                       
   Parenteral anticoagulant+warfarin   28 (17.0%)                24 (17.3%)                       
   DOAC                                34 (20.6%)                56 (40.3%)                       
    Rivaroxaban                        31 (91.2%)                56 (100.0%)                      
    Apixaban                           3 (8.8%)                  0                                
   Not documented                      3 (1.8%)                  2 (1.4%)                         
  PE and PE+DVT                                                                                   p=0.0039
   Parenteral anticoagulant alone      45 (60.0%)                19 (33.3%)                       
   Parenteral anticoagulant+warfarin   6 (8.0%)                  12 (21.1%)                       
   DOAC                                21 (28.0%)                25 (43.9%)                       
    Rivaroxaban                        19 (90.5%)                25 (100.0%)                      
    Apixaban                           2 (9.5%)                  0                                
   Not documented                      3 (4.0%)                  1 (1.8%)                         
  DVT alone                                                                                       p=0.0015
   Parenteral anticoagulant alone      55 (61.1%)                38 (46.3%)                       
   Parenteral anticoagulant+warfarin   22 (24.4%)                12 (14.6%)                       
   DOAC                                13 (14.4%)                31 (37.8%)                       
    Rivaroxaban                        12 (92.3%)                31 (100.0%)                      
    Apixaban                           1 (7.69)                  0                                
   Not documented                      0                         1 (1.2%)                         
  Follow-up\*                                                                                     
   Family doctor                       22 (13.3%)                39 (28.1%)                       
   Return to ED                        1 (0.6%)                  4 (2.9%)                         
   Specialist                          4 (2.4%)                  9 (6.5%)                         
   VTE clinic                          133 (80.6%)               47 (33.8%)                       
   Anticoagulation clinic              3 (1.8%)                  0                                
   Other                               8 (4.9%)                  36 (25.9%)                       
   Not documented                      3 (1.8%)                  20 (14.4%)                       

\*Not mutually exclusive.

DOAC, direct oral anticoagulant; DVT, deep vein thrombosis; ED, emergency department; PE, pulmonary embolism; VTE, venous thromboembolism.

Overall, DOACs were used more commonly for PE (34.0%) than DVT (24.5%) (p=0.04) with this use being driven by the Edmonton sites, as only a small numbers of patients (n=12) with PE were discharged from ED in rural Alberta or Regina. No difference was observed for DOAC use among those having a sPESI score of 0 (35.8%) or score ≥1 (31.3%) (p=0.90). Similarly, no difference was observed for DOAC use based on clinical severity of low risk (32.6%; 42/129) versus submassive (50.0%; 7/15) PE (p=0.09) (data not shown). Overall, the prescription of a DOAC was more common for proximal DVTs (28.4%) compared with distal DVTs (17.3%) (p\<0.001). Selection of a DOAC was not influenced by renal function, with 20% (n=2/10), 23.5% (8/34) and 30.3% (86/284) receiving a DOAC with a Cr Cl \<30, 30--50 and \>50 mL/min, respectively.

Of those going home on a DOAC, 79.3% were prescribed a dosing regimen consistent with the Canadian product monographs, while 7.8% were prescribed a regimen not in alignment with monograph recommendations and 12.9% did not have a regimen documented in the chart ([table 4](#T4){ref-type="table"}). Of those with an identified discordant DOAC dose, the majority (n=7; 77.8%) had incorrect drug--dose sequencing and two (22.2%) were prescribed rivaroxaban despite having a Cr Cl \<30 mL/min.

###### 

Dosing for DOACs on discharge from the emergency department

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  DOAC regimen\*                                                    Edmonton academic sites n=34   Edmonton community-based sites\   Rural Alberta\   Regina n=10   Total n=116
                                                                                                   n=56                              n=16                           
  ----------------------------------------------------------------- ------------------------------ --------------------------------- ---------------- ------------- -------------
  Rivaroxaban                                                       n=31 (91.2%)                   n=56 (100%)                       n=15 (93.8%)     n=9 (90.0%)   111 (95.7%)

   15 mg two times per day, 20QD†                                   13 (41.9%)                     38 (67.9%)                        10 (66.7%)       8 (88.9%)     69 (62.2%)

   15 mg two times per day†                                         12 (35.3%)                     7 (12.5%)                         2 (13.3%)‡       1 (11.1%)     22 (19.8%)

   15 mg two times per day, 15QD                                    0                              1 (1.8%)                          0                0             1 (0.9%)

   15 mg QD                                                         1 (3.2%)                       0                                 0                0             1 (0.9%)

   20 mg QD                                                         1 (3.2%)                       0                                 0                0             1 (0.9%)

   Other                                                            0                              1 (1.8%)                          1 (6.7%)         n=0           2 (1.8%)

   Not documented                                                   4 (12.9%)                      9 (16.1%)                         2 (13.3%)        0             15 (13.5%)

  Apixaban                                                          n=3                            n=0                               n=1              n=1           5 (4.3%)

   10 mg two times per day x 7 days then 5 mg two times per day\*   2                              0                                 1                0             3

   5 mg two times per day                                           1                              0                                 0                1             2

  Dosing as per PM                                                  27 (79.4%)                     45 (80.4%)                        11 (68.8%)       9 (90%)       92 (79.3%)

   Dosing outside PM                                                3 (8.8%)                       2 (3.6%)                          3 (18.8%)        1 (10%)       9 (7.8%)

   Not documented                                                   4 (11.8%)                      9 (16.1%)                         2 (12.5%)        0             15 (12.9%)
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Dosing as per product monographs: rivaroxaban 15 mg two times per dayx21 days then rivaroxaban 20 mg daily; apixaban 10 mg two times per dayx7 days then apixaban 5 mg two times per day; parenteral anticoagulant x 5--10 days followed by dabigatran 150 mg two times per day.[@R3]

†Classified as dosing consistent with Health Canada-approved product monograph.

‡Both had creatinine clearance \<30 mL/min; hence were classified as discordant with Health Canada-approved product monograph.

DOAC, direct oral anticoagulant; PM, product monograph.

On discharge from the ED, most patients in Edmonton were to follow up with the academic hospital-based VTE clinics (59.2%), with this being more common at the academic sites (80.6%) compared with the community-based sites not having VTE clinics (33.8%). In rural Alberta and Regina, follow up with the family doctor was most common (53.3% and 56.6%, respectively).

Discussion {#s4}
==========

In this cohort of patients discharged directly from ED with a VTE, traditional therapy with a parenteral anticoagulant±warfarin therapy was the most used strategy (70.7%) while 27.8% of patients were discharged on a DOAC. Variation was observed across the sites with highest utilisation of traditional therapy in Regina (75.9%) and DOAC in rural Alberta (53.3%), while in Edmonton, the predominant strategy was a parenteral anticoagulant alone (51.6%). Potential reasons for this variation include timing of the data collection in relation to Health Canada approval of the DOACs, availability of local outpatient VTE clinics (at the Edmonton-based academic sites but not Regina or rural Alberta) and specialisation of prescribers (EDs in rural Alberta are staffed by primary care physicians while EDs in Edmonton and Regina are staffed by emergency medicine physicians). Further, the academic sites in Edmonton more frequently referred to an in-house VTE clinic compared with Edmonton-based community sites (80.6% vs 33.8%) and predominantly used a parenteral anticoagulant strategy alone as compared with those that did not refer to VTE clinic (60.6% vs 41.0%), deferring the decision on future oral therapy to the VTE clinic. These clinics advocate for the use of a DOAC, and hence our reported rates of DOAC use directly out of the ED are likely an underestimate of use in the Edmonton area.

Within the Edmonton area, 43.4% of the cohort of patients discharged from the ED with VTE had a PE, whereas only 7.2% of the cohort from Regina had a PE. Current guidelines suggest that patients with low-risk PE whose home circumstances are adequate should be treated at home or discharged early over a standard discharge that typically follows the first 5 days of treatment.[@R12] Notably, with the Edmonton area, a small portion of patients were identified to have submassive PE (n=15, 11.4%) while all patients in Regina (n=6) and rural Alberta (n=6) were deemed low risk. Clinician comfort and the ability to ensure prompt care in the community likely influenced these decisions. Among the academic Edmonton centres, 60% (n=45/75) with PE were discharged from the ED on a parenteral anticoagulant alone with the majority (n=40/45, 89%) to be seen within the ambulatory VTE clinic for clinical assessment. In the community-based Edmonton hospitals, 33.3% (19/57) were discharged on a parenteral anticoagulant, with 57.9% (11/19) being referred to a VTE clinic or local intravenous clinic with nurse follow-up. Overall, regardless of the therapy at ED discharge, 66.7% (88/132) of patients in the Edmonton area being discharged with PE had clear documentation of follow-up within either a VTE or intravenous clinic, imparting comfort with ongoing care following ED discharge. This is affirmed by an audit of 175 patients with PE within Kaiser Permanente in Northern California wherein 56 (32.0%) patients were discharged within 24 hours of ED presentation.[@R24] Notably, those at higher risk (PESI class III to V) received more prompt outpatient follow-up (81% within 3 days) relative to those deemed low risk (65% within 3 days). In contrast, Regina does not have a local VTE clinic to offer timely, coordinated care to this population, and this may partially explain why only a small proportion of low-risk PE patients were discharged directly from the ED.

Practices in rural Alberta were different from that observed in the urban centres. The ED physicians in rural Alberta were, for the most part, the same family physicians seeing patients in the community setting. The follow-up plan with those in rural Alberta reflected this, being either with the family doctor (53.3%) or to return to the ED (23.3%). In rural Alberta, patients with DVT could only access ultrasonography at community-based diagnostic centres. Given this, it was common to have patients return to the ED for a parenteral anticoagulant daily until diagnostic confirmation could be performed in the community. Additionally, documentation in the rural ED was less complete in the form of confirming the diagnostic result given that patients would often follow up with their physician in the community, reflected by the lowest rate of inclusion (16.2%). Lastly, two of the three rural sites staffed hospital pharmacists that sought additional training in anticoagulation management and had worked collaboratively within the local community. Use of DOACs was generally supported by these pharmacists, perhaps contributing to the higher rate of use in rural Alberta (53.3%) versus the urban Edmonton sites (29.6%). Moreover, less laboratory testing with the use of the DOACs in a rural versus urban setting is advantageous given the distances needed to travel to laboratories.

While use of DOACs was modest in our study (27.8%), it is notable only rivaroxaban had an indication for VTE in Canada during the entire duration of our audit (March 2014 to April 2015), and provincial drug remuneration was only in place for DVT (not PE) with rivaroxaban for the entire audit year. Rivaroxaban was the DOAC most commonly used (95.7%), with a minority of patients prescribed apixaban (4.3%). Relative to other literature reports for DOAC use for acute VTE, our rates are modest.[@R25] A single-centre evaluation of 256 patients admitted to the ED or hospital in Quebec, Canada with VTE from February to September 2013 reported 17.6% of patients were discharged on rivaroxaban.[@R25] A study assessing use among 328 patients with PE in France reported an increase in DOAC use at discharge from the 2014 audit (23.2%) to the 2015 audit (40.1%).[@R26]

Of those having documented dosing of a DOAC at ED discharge in our study, the majority (91.1%, 92/101) complied with that in the product monographs. Limited data are available for comparison. A small Australian audit of 39 patients receiving a DOAC for acute VTE reported 84.6% to be appropriately dosed.[@R27] In the larger, non-interventional study of rivaroxaban for DVT, among 2619 prescribed rivaroxaban, 93.7% received the correct initial dosing of rivaroxaban 15 mg two times per day.[@R28] As DOAC therapy and therapy options are likely to expand, it is imperative that drug--dose regimens are appropriately prescribed for this indication.

Strengths and limitations {#s5}
=========================

To our knowledge, our data are the largest cohort of acute VTE patients managed directly out of EDs and represents a full year (1 April 2014 to 31 March 2015) of patients presenting with acute VTE at all institutions. We do acknowledge that rivaroxaban was the only DOAC with approval by Health Canada before this time interval, and our time interval reflects the early uptake of DOACs for the treatment of acute VTE. Approval of all other agents followed rivaroxaban, and practice patterns today may be different than identified during our evaluation interval, setting the stage for further assessment of uptake over time. Moreover, differing sample sizes between Edmonton, Regina and rural Alberta were achieved---in particular a low sample size in rural Alberta. Although small, we believe these data offer a reflective representation of these practice areas, given we spanned a full year of data and volumes are reflective of local (with catchment area) populations. Comparing these centres for the same time interval has provided us the opportunity to compare practices in different jurisdictions (eg, discharging of patients with PE directly from the ED, follow-up patterns and the influence of dedicated ambulatory VTE clinics following ED discharge) that offer healthcare system insight into clinician practices and institution use (namely comfort with discharging directly from the ED). We sought to identify practice patterns, and therefore conducted a retrospective medical record review. Given this design, we were able to accurately review individual charts, but were limited by the documentation available in the ED or hospital chart. Missing data elements (weight, serum creatinine) have been identified and reported, accordingly. Moreover, given the inclusion of two provinces and volume of sites, three data abstractors were necessary to conduct all the chart audits. To minimise bias and errors in coding, a key was created, teleconferences occurred and limits were programmed into REDCap for data elements with quality assurance checks performed for each site. Lastly, given our design and a priori identified outcomes, we were unable to follow patients after leaving the hospital, and therefore are unable to address outcomes/events during this time interval.

Conclusion {#s6}
==========

Overall, we observed traditional therapy (parenteral anticoagulant±warfarin) to be used most in our study (70.7%), but report reasonable uptake of DOAC use (27.8%), with more usage in Edmonton (29.6%) than Regina (12.1%) and the most use in rural Alberta (53.3%). The Edmonton area discharged more patients directly from the ED with PE than the Regina area (43.4% vs 7.2%, respectively), with the majority of these patients being referred to a specialised VTE ambulatory clinic for follow-up in the community. Access to prompt ambulatory VTE follow-up appeared to influence both the comfort of discharging patients directly from the ED with PE as well as the therapy selected within the ED (most commonly a parenteral anticoagulant)---a finding that may offer insight into future resource allocation. As use of the DOACs is likely to increase for acute VTE management, it is paramount that prescribers implement the appropriate drug--dose sequences. Future evaluations to ensure appropriateness of DOAC use should ensue, as well as studies designed to follow patient outcomes after being discharged directly from the ED.
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